29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27 2014 9 5 Bisphosphonate related osteonecrosis of jaw; BRONJ 2002 Marx RE, Stern DS Oral and Maxillofacial pathology 2,3 BRONJ 4,5 BRONJ BP
32 1 BRONJ BRONJ II 2008 2012 BRONJ 19 76.4 36 98 8 11 1 2 3 BRONJ 4 BP 5 6 7 8 9 BRONJ 6 1 III 1 2 1 1 14 3 2 BP 3 7 5 1.8 0.6 4 2 3 BRONJ 0 13 2 5 3 1 1 0 3 4 BP BP
BRONJ 33 1 2 4 5 10 4 5 6 10 9 5 3 1 6 7 α-streptcoccus Neisseria species 7 8 8 9 9
34 3 0 1 4 6 10 6 6 2 2 1 2 11 BP BP 4 15 IV BP BRONJ 0.0 4.3 0.0 27.5 7 12 47.8 10.1 BRONJ 13 BRONJ 14 BP BRONJ 15 BRONJ 19 15 BRONJ BRONJ 19 4
BRONJ 35 5 A 10 mg 0.5 mg B 1.8 mg 1.88 125 mg 2 mg
36 6 7 α-streptcoccus Neisseria species 15 Bacteroides 2 Prebotella 2
BRONJ 37 8 1 g S 600 mg 100 mg 2 g MS 100 mg Meiji Seika 200 mg 500 mg 250 mg 1 g 500 mg 9...
38 16 QOL 5 BP BP P-C-P R1 17 BP BP 18 5 3 1 BRONJ BRONJ BRONJ 19 BRONJ BRONJ BP BP BP 20 RANKL receptor activator of nuclear factor-kb ligand 1.8 21 23 BP Actinomyces, Veillonella, Eikenella, Moraxella, Fusobacterium, Bacillus, Staphylococcus, Streptococcus, and Selenomonas 24,25
BRONJ 39 26 28 BRONJ BP BRONJ BP 1 Coleman RE: Future directions in the treatment and prevention of bone metastates. Am J Clin Oncol 25: S32 S38, 2002. 2 Wang, J., Gooder, N.M.: Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61: 1104 1107, 2003. 3 Marx, R.E.: Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws. J oral Maxillofac Surg 61: 1115 1118, 2003. 4 1 52: 416 419, 2006. 5 1 53: 28 32, 2007. 6 2012 7 Bianchi ML, Limonta C, et al. Comment on: bisphosphonates and osteonecrosis of the jaw. J Rheumatol 47: 383, 2008. 8 Boonyapakorn T, Schirmer I, et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44: 857 869, 2008. 9 Mavrokokki T, Cheng A, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65: 415 423, 2007. 10 Murad OM, Arora S, et al. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr pract 13: 232 238, 2007. 11 Christodoulou C, Pervena A, et al. Combination of the jaw more frequently than bisphosphonates alone. Oncology 76: 209 211, 2009. 12 Sedghizadeh PP, Stanley K, et al. Oral bisphosphonates use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 140: 61 66, 2009. 13 58: 342 349, 2012. 14 Yoneda T, et al. Bisphosphonate-Related Osteonecrosis of the Jaw: Position Paper from the Allied Task Force. Committee of Japanese Society for Bone and Mineral Research, Osteoporosis Society Japan, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacial Surgeons, J Bone Miner Metab (in press) 15 Urade M, et al. Nationwide Survey for Bisphosphonate-Related Osteonecrosis of the Jaws in Japan. J Oral Maxillofac Surg 69: e364 e371 (2011) 16 1995. 17 Bartl R, Frisch B. 138 154, 2007. 18 Philipp S, Moritz B, et al. The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw result of a clinical case series with an average follow-up of 20 months. Clin Oral Invest DOI 10.1007/s00784-013-1092-2 19 American Dental Association Council on Scientific Affairss: Dental management of patients receiv-
40 ing oral bisphosphonate therapy Expert panel recommendations. JADA 137: 1144 1150, 2006. 20 World of Bisphosphonate; illustrated mechanism of action and clinical use. 2001. 21 Henry DH, et al.: J Clin Oncol. 2011; 29(9): 1125 1132. 22 Stopeck AT, et al.: J Clin Oncol. 2010; 28(35): 5132 5139. 23 Fizazi K, et al.: Lancet. 2011; 377(9768): 813 822. 24 Bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. Am Fam Physician. 2012 Jun 15; 85(12): 1134 41. 25 Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol. 2012 Mar-Apr; 52(2): 265 70. 26 Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg. 2011 Jul; 49(5): 335 42. 27 Clinical experience with spiramycin in bisphosphonate-associated osteonecrosis of the jaw. Int J Immunopathol Pharmacol. 2010 Apr-Jun; 23(2): 619 26. 28 0 1 0385-0684 39 13 Page2573 2575 2012.12